Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

Key points – Lenalidomide plus rituximab as induction and maintenance therapy for MCL can achieve durable remissions. Chronic therapy-associated adverse events are generally non-accumulative, and remain manageable.